• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Corrona Acquires Patient Experience Company HealthiVibe

by Fred Pennic 12/10/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Corrona Acquires Patient Experience Company HealthiVibe

– Corrona acquires patient experience company HealthiVibe to further expand its presence in the patient experience marketplace.

– HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives at every stage of the product lifecycle.

Corrona, LLC, a provider of real-world observational and syndicated registry data, announced today that it has acquired HealthiVibe, LLC, an Arlington, VA-based patient experience company. Financial details of the acquisition were not disclosed.

Founded in 2014, HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives at every stage of the product lifecycle.  The company leverages innovative, co-creation models and global online analytic platforms to provide clients with the tools and the expertise to gather, analyze and apply deep patient insights to optimize clinical trials and enhance overall product commercialization efforts.

Acquisition Benefits for Corrona

Corrona provides real-world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators.  The acquisition of HealthiVibe complements and strengthens Corrona’s strong presence in disease registries by providing market-leading expertise in supporting innovative, evidence-based patient engagement initiatives across the product lifecycle.

With projects in over 60 countries and more than 90 indications, HealthiVibe also brings valuable global experience and breadth to Corrona.  Corrona operates six major autoimmune registries across the US, Canada, and Japan, collecting data from over 500 participating investigator sites.

“We believe this is a perfect fit for both HealthiVibe and Corrona,” said Abbe Steel, CEO of HealthiVibe.  “In response to the FDA’s Patient-Focused Drug Development Initiative and the 21st Century Cures Act, pharmaceutical companies are investing time and energy in patient insights and real-world evidence.  Marrying those two by linking together HealthiVibe’s patient insight background with Corrona’s industry-leading real-world evidence data, and drawing on Corrona’s deep relationships with sites and patients will bring significant value to our clients.”

In addition to her title of CEO of HealthiVibe, Abbe will also be taking on the newly created role of Chief Patient Officer at Corrona.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: biopharmaceutical, Clinical Trials, FDA, Healthcare Mergers & Acquisitions, patient engagement, Patient Experience, Payers

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |